Giredestrant-Everolimus Improves PFS in Pretreated Breast Cancer

This phase 3 trial compared giredestrant plus everolimus against standard endocrine therapy plus everolimus in ER-positive, HER2-negative advanced breast cancer patients previously treated with a CDK4/6 inhibitor. The trial reported median progression-free survival of 10.0 versus 5.5 months in patients with mutated tumors, and 8.8 versus 5.5 months in the overall population, both favoring giredestrant-everolimus. Adverse event rates, including stomatitis, diarrhea, and anemia, were reported as similar between the two groups.

Most relevant for: Patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed after a CDK4/6 inhibitor plus endocrine therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.